Regencell Bioscience Shares Down 14.7% to $14.27
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Regencell Bioscience is down -14.7%, or -$2.46 to $14.27.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Relevant Gold Corp. Announces Shareholder Meeting Voting Results
- Shareholder Meeting Outcomes: At the shareholder meeting held in Vancouver, 61 shareholders attended, representing approximately 54.75% of the company's issued common shares, with all proposals approved, including setting the number of directors at six and electing all nominees.
- New Director Appointment: Mal Karwowska was elected to the board, succeeding Ron Parratt, who did not seek re-election; Karwowska's extensive experience in corporate development and capital markets is expected to add strategic value to the company.
- Auditor Appointment: The meeting also approved Smythe LLP as the company's auditor and authorized the board to determine the auditor's remuneration, which will enhance the company's financial transparency and compliance.
- Incentive Plan Re-approval: The company re-approved its Omnibus Equity Incentive Compensation Plan, aimed at attracting and retaining key talent, thereby supporting the company's long-term growth strategy in gold exploration.
See More
Faruqi & Faruqi Encourages Regencell Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Regencell Bioscience Holdings Limited, focusing on securities purchased between October 28, 2024, and October 31, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that June 23, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Partner Josh Wilson has provided direct contact numbers, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to client support.
- Potential Market Impact: Such legal actions could negatively affect Regencell's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, which adversely affected the company's reputation and legal standing.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 28, 2024, to October 31, 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and potential regulatory scrutiny.
- SES AI Misleading Business Prospects: From January 29, 2025, to March 4, 2026, SES AI is alleged to have overstated its business prospects, as deals with companies lacking operations did not yield expected revenues, casting doubt on its growth outlook for 2026.
- FS KKR Capital Overstatements: Between May 8, 2024, and February 25, 2026, FS KKR is accused of overstating the effectiveness of its portfolio restructuring efforts, which negatively impacted its financial results and rendered previous positive statements misleading.
- Graphic Packaging Operational Issues: From February 4, 2025, to February 2, 2026, Graphic Packaging is alleged to have downplayed significant inventory management issues and reduced demand, leading to unreliable financial guidance and adverse effects on its business performance.
See More
Regencell Bioscience Faces Class Action Over Alleged Misrepresentations
- Lawsuit Background: Regencell Bioscience Holdings Limited (NASDAQ:RGC) is facing a class action lawsuit for alleged misleading statements regarding its R&D budget versus its market valuation, with investors able to seek lead plaintiff status until June 23, 2026.
- R&D Spending vs. Market Valuation: The company reported approximately $0.95 million in R&D expenditures for the fiscal year 2025, starkly contrasting with its market valuation of around $14 billion, highlighting a significant disconnect that could lead to substantial investor losses.
- Stock Price Volatility: Following the disclosure of a U.S. Department of Justice subpoena and investigation, RGC's shares fell by $3.09, or 18.56%, on November 3, 2025, indicating increasing market concerns regarding the company's fundamentals.
- Poor Operational Status: With only 12 employees and no revenue or approved products since its inception, Regencell's stock price surged to $78 in June 2025, revealing a stark disparity between market optimism and the company's actual operational performance.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply to be lead plaintiff by June 23, 2026, to potentially receive compensation without any out-of-pocket costs.
- Counsel Selection Advice: Investors are encouraged to choose qualified counsel with a proven track record; Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its industry leadership.
- Case Details Revealed: The lawsuit alleges that Regencell made false or misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, indicating the company's vulnerability to regulatory scrutiny.
- Investor Rights Protection: Although the class has not yet been certified, investors can still select their counsel or remain absent, ensuring that their ability to share in any potential future recovery is not contingent on serving as lead plaintiff, thus providing flexibility and choice in the legal process.
See More
Relevant Gold Corp. Announces Shareholder Meeting Voting Results
- Shareholder Meeting Outcomes: At the shareholder meeting held in Vancouver, 61 shareholders attended, representing approximately 54.75% of the company's issued common shares, with all proposals approved, including setting the number of directors at six and electing all nominees.
- New Director Appointment: Mal Karwowska was elected to the board, succeeding Ron Parratt, who did not seek re-election; Karwowska's extensive experience in corporate development and capital markets is expected to add strategic value to the company.
- Auditor Appointment: The meeting also approved Smythe LLP as the company's auditor and authorized the board to determine the auditor's remuneration, which will enhance the company's financial transparency and compliance.
- Incentive Plan Re-approval: The company re-approved its Omnibus Equity Incentive Compensation Plan, aimed at attracting and retaining key talent, thereby supporting the company's long-term growth strategy in gold exploration.
See More
Faruqi & Faruqi Encourages Regencell Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Regencell Bioscience Holdings Limited, focusing on securities purchased between October 28, 2024, and October 31, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that June 23, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Partner Josh Wilson has provided direct contact numbers, encouraging affected investors to call 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a commitment to client support.
- Potential Market Impact: Such legal actions could negatively affect Regencell's stock price, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, which adversely affected the company's reputation and legal standing.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 28, 2024, to October 31, 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and potential regulatory scrutiny.
- SES AI Misleading Business Prospects: From January 29, 2025, to March 4, 2026, SES AI is alleged to have overstated its business prospects, as deals with companies lacking operations did not yield expected revenues, casting doubt on its growth outlook for 2026.
- FS KKR Capital Overstatements: Between May 8, 2024, and February 25, 2026, FS KKR is accused of overstating the effectiveness of its portfolio restructuring efforts, which negatively impacted its financial results and rendered previous positive statements misleading.
- Graphic Packaging Operational Issues: From February 4, 2025, to February 2, 2026, Graphic Packaging is alleged to have downplayed significant inventory management issues and reduced demand, leading to unreliable financial guidance and adverse effects on its business performance.
See More
Regencell Bioscience Faces Class Action Over Alleged Misrepresentations
- Lawsuit Background: Regencell Bioscience Holdings Limited (NASDAQ:RGC) is facing a class action lawsuit for alleged misleading statements regarding its R&D budget versus its market valuation, with investors able to seek lead plaintiff status until June 23, 2026.
- R&D Spending vs. Market Valuation: The company reported approximately $0.95 million in R&D expenditures for the fiscal year 2025, starkly contrasting with its market valuation of around $14 billion, highlighting a significant disconnect that could lead to substantial investor losses.
- Stock Price Volatility: Following the disclosure of a U.S. Department of Justice subpoena and investigation, RGC's shares fell by $3.09, or 18.56%, on November 3, 2025, indicating increasing market concerns regarding the company's fundamentals.
- Poor Operational Status: With only 12 employees and no revenue or approved products since its inception, Regencell's stock price surged to $78 in June 2025, revealing a stark disparity between market optimism and the company's actual operational performance.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply to be lead plaintiff by June 23, 2026, to potentially receive compensation without any out-of-pocket costs.
- Counsel Selection Advice: Investors are encouraged to choose qualified counsel with a proven track record; Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, highlighting its industry leadership.
- Case Details Revealed: The lawsuit alleges that Regencell made false or misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, indicating the company's vulnerability to regulatory scrutiny.
- Investor Rights Protection: Although the class has not yet been certified, investors can still select their counsel or remain absent, ensuring that their ability to share in any potential future recovery is not contingent on serving as lead plaintiff, thus providing flexibility and choice in the legal process.
See More
